Top Healthcare Stocks
Healthcare stocks gave up small gains earlier in today's session
and were finishing today with small declines and the NYSE
Healthcare Sector Index declining about 0.2% and shares of
healthcare companies in the S&P 500 falling 0.1% as a
In company news, Enzymotec (
) shares tumbled over 30%, falling to an all-time low after
reporting Q1 revenue trailing Wall Street projections.
The Israeli company developing lipid-based products reported a
29.7% year over year increase in revenue to $17.9 million during
the three months ended March 31, lagging the Capital IQ consensus
by $1.5 million. It earned $0.24 per share, beating analyst
projections by $0.07 per share.
ENZY issued in-line guidance for the full year ending in
December, forecasting EPS in a range of $0.64 to $0.94 on $90
million to $110 million in revenue. Analysts, on average, are
looking for a $0.86 per share profit on just under $93 million in
The company's shares were down 29% at $14.35 a share in recent
trade, earlier falling to $13.60 a share, its lowest price since
its Sept. 27, 2013, initial public offering of stock.
Enzymotec also issued guidance for the full year 2014 of 64
cents a share to 94 cents a share, while analysts expect 86 cents a
share. The company expects full year revenue based on the
proportionate consolidation method of $90 million to $110 million,
while analysts expect $92.95 million. Based on the equity method,
Enzymotec expects revenue of $68 million to $85 million.
In other sector news,
(+) CNAT, Q1 net loss of $0.34 per share trails analyst
estimates by $0.01. Company did not generate any revenue during the
three months ended March 31.
(-) PETX, Q1 net loss of $0.34 per share matches Capital IQ
consensus. The company had no revenue during the quarter.
Copyright (C) 2014 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.